Enrico Picozza Biography and Net Worth

Director of DermTech

Enrico Picozza is a partner of HLM Venture Partners, a venture firm that invests in tech-enabled healthcare services, healthcare information technology, and medical device and diagnostics companies. He is also currently a director of AbleTo, mPulseMobile, RubiconMD and a board observer to OnShift. His previous board appointments included Vericare (sold to MedOptions), Spinal Kenetics (sold to Orthofix), Transend Medical (sold to Alcon), Medicalis (sold to Siemens), Aventura (sold to Philips), SensAble Technologies (sold to 3D Systems) and was a board observer and special advisor to Interlace Medical (sold to Hologic), and Tandem Diabetes (NASDAQ). Prior to joining HLM as a Venture Partner, Enrico co-founded HTS Biosystems, Inc., an early developer of platforms for drug discovery and point of care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer. Prior to HTS, Enrico held leadership positions with PerkinElmer, Inc. and Applied Biosystems, Inc. Enrico was part of the startup team within Perkin Elmer involved in the development and commercialization of PCR, the revolutionary DNA-replicating technology that enabled the development of some of the most significant advancements in molecular biology. Enrico is the holder of nine patents and has been recognized by the Smithsonian Institute for his achievements in PCR. He is the author of numerous scientific papers and has been a frequent international speaker. Enrico attended the University of Connecticut for undergraduate and postgraduate studies in the major Molecular and Cell Biology.

What is Enrico Picozza's net worth?: The estimated net worth of Enrico Picozza is at least $0.00 as of May 25th, 2021. Mr. Picozza owns 14,000 shares of DermTech stock worth more than $0 as of November 5th. This net worth approximation does not reflect any other assets that Mr. Picozza may own. Learn More about Enrico Picozza's net worth.
How do I contact Enrico Picozza?: The corporate mailing address for Mr. Picozza and other DermTech executives is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. DermTech can also be reached via phone at (858) 450-4222 and via email at [email protected]. Learn More on Enrico Picozza's contact information.
Has Enrico Picozza been buying or selling shares of DermTech?: Enrico Picozza has not been actively trading shares of DermTech in the last ninety days. Most recently, Enrico Picozza sold 4,703 shares of the business's stock in a transaction on Tuesday, May 25th. The shares were sold at an average price of $40.01, for a transaction totalling $188,167.03. Following the completion of the sale, the director now directly owns 14,000 shares of the company's stock, valued at $560,140. Learn More on Enrico Picozza's trading history.
Who are DermTech's active insiders?: DermTech's insider roster includes John Dobak (CEO), Claudia Ibarra (COO), Scott Pancoast (Director), Enrico Picozza (Director), Kevin Sun (CFO), and Todd Wood (Insider). Learn More on DermTech's active insiders.
Are insiders buying or selling shares of DermTech?: In the last year, insiders at the sold shares 5 times. They sold a total of 13,436 shares worth more than $20,494.84. The most recent insider tranaction occured on December, 11th when CFO Kevin M Sun sold 447 shares worth more than $648.15. Insiders at DermTech own 5.1% of the company. Learn More about insider trades at DermTech.
Information on this page was last updated on 12/11/2023.

Enrico Picozza Insider Trading History at DermTech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/25/2021	Sell	4,703	$40.01	$188,167.03	14,000
5/20/2021	Sell	94,719	$36.73	$3,479,028.87	14,000
5/18/2021	Sell	21,126	$37.42	$790,534.92	14,000
2/28/2020	Buy	76,228	$10.50	$800,394.00

Enrico Picozza Buying and Selling Activity at DermTech

DermTech Company Overview

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Today's Range

Now: N/A

50 Day Range

MA: $0.19

$0.05

$0.42

2 Week Range

Now: N/A

Volume

3,662,300 shs

Average Volume

1,065,175 shs

Market Capitalization

$3.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.48

NASDAQ small cap that could be gearing up for a massive short squeeze.

From Huge Alerts | Ad

A Heavy Short Interest Could Lead to a Monstrous Short Squeeze for this Tiny NASDAQ Healthcare Firm!

See how this NASDAQ Bio-tech is offering viable solutions